Overview Services Applications Highlights Unified Solutions Get Started FAQs Products
Advancing Mechanistic Insights Through Targeted Protein Restoration
Creative Biolabs delivers mRNA development services for protein replacement research, leveraging non-viral delivery platforms and engineered mRNA constructs to enable controlled expression of therapeutic proteins exclusively for preclinical investigation of genetic disorders, metabolic dysfunctions, and rare disease pathogenesis.
Featured Services
-
Expression Optimization: AI-driven UTR/poly-A tail engineering enhances translational efficiency while minimizing immune recognition, enabling sustained protein production in target tissues.
-
Epigenetic Adaptation: Codon-deoptimized sequences resist heterochromatin silencing in disease microenvironments.
-
Co-Transfection Systems: Modular co-encapsulation of chaperone mRNAs ensures proper folding of complex proteins.
Targeted Delivery Platforms
-
Organ-Selective LNPs: Peptide-guided nanoparticles for liver/lung/CNS delivery validated in multi-species biodistribution studies.
-
Stimuli-Responsive Release: Biomarker-activatable formulations enable context-dependent protein expression.
Multi-Omics Validation Framework - Comprehensive Efficacy Assessment
-
Functional Restoration: Activity assays
-
Spatial Proteomics: Multiplexed IHC tracking of protein distribution in complex tissues
-
Transcriptomic Signatures: Analysis of downstream pathway modulation
-
Cell-Specific Biodistribution: FACS-isolated organ-specific cell profiling
Fig.1 mRNA Engineering Service Workflow for Protein Replacement.
Related mRNA Services
Immunotherapy related mRNA Development
-
Tumor-Specific Antigen Design: Engineering neoantigen/TSA-targeting constructs
-
Immune Checkpoint Modulation: Temporally regulating PD-1/CTLA-4 pathways
-
Adoptive Cell Therapy Enhancement: Optimizing CAR/TCR/TIL functional persistence
Genetic Disease-related mRNA Development
-
Mutation Correction: Delivering functional protein variants
-
Splice-Switching: Modulating aberrant RNA processing
-
Epigenetic Reprogramming: Transiently editing chromatin states
Regenerative Medicine-related mRNA Development
-
Non-integrative Reprogramming: Generating stem/progenitor cells
-
Tissue-Specific Differentiation: Directing lineage commitment signals
-
Microenvironment Modulation: Expressing niche-supporting factors
Therapeutic Antibody-coding mRNA Development
-
Multispecific Antibody Expression: Engineering bispecific/trispecific formats
-
In Vivo Antibody Production: Bypassing recombinant manufacturing
-
Epitope-Specific Validation: Testing antigen-binding domain efficacy
mRNA Pharmacology Optimization
-
Delivery Vector Screening: Profiling LNP/polymer transfection efficiency
-
Immunogenicity Reduction: Engineering nucleotide/UTR modifications
-
Tissue-Specific Biodistribution: Mapping payload delivery kinetics
mRNA Vaccine Development
-
Pathogen Antigen Design: Encoding conserved/emergent immunogens
-
Adjuvant Co-Delivery: Coordinating innate immune activation
-
Cross-Reactivity Evaluation: Assessing variant strain coverage
Technology Evolution: From Vaccines to Complex Disease Modeling
Recent breakthroughs have demonstrated mRNA technology's capacity to transcend traditional vaccine applications, enabling dynamic protein expression in vivo for mechanistic research. Key advancements include:
-
Temporal Control: Transient expression (days to weeks) allows kinetic studies of protein function recovery, critical for modeling enzymatic pathways in metabolic disorders.
-
Spatiotargeting: Organ-specific LNPs (e.g., liver-homing peptides for phenylalanine hydroxylase delivery) achieve >80% target tissue enrichment, minimizing off-target effects in multi-organ systems.
-
Co-Delivery Systems: Single-vector encapsulation of corrective mRNAs + chaperones ensures proper folding of complex proteins (e.g., lysosomal enzymes with glycosylation cofactors).
Transformative Research Applications
Fig.2 Transformative Research Applications for Protein Replacement.
Why This Technology Empowers Your Research
The convergence of tunable expression, modular co-delivery, and precision targeting positions mRNA as an unparalleled tool for:
-
Disease Pathogenesis Modeling: Recapitulate protein dysfunction trajectories in genetically accurate systems.
-
Combinatorial Intervention Screening: Test rescue strategies involving multiple chaperones/enzymes without viral integration risks.
-
Functional Genomic Validation: Couple mRNA delivery with targeted transcriptional modulation systems to dissect regulatory nodes in protein homeostasis networks.
Integrated mRNA Technology Platform - Unified Solutions for Protein Replacement Research
Creative Biolabs integrates five core mRNA technology modules into a seamless workflow, delivering end-to-end support for protein mechanism studies. This synergistic platform enables researchers to overcome fragmentation in conventional approaches, providing a unified path from target design to functional validation.
Technology Modules & Research Applications
|
Module
|
Key Innovations
|
Protein Replacement Research Value
|
|
Custom mRNA Synthesis
|
-
AI-optimized codon/UTR design
|
Generates high-fidelity templates encoding complex proteins with >80% functional yield
|
-
Scaffold-free IVT systems
|
|
Custom mRNA Modification
|
-
Pseudouridine/N1-methylpseudouridine incorporation
|
Reduces immunogenicity by >60% in chronic disease models, enabling repeated dosing studies
|
|
|
|
Custom mRNA Delivery Vehicle Development
|
-
Stimuli-responsive lipid libraries
|
Achieves 90% target-organ specificity in multi-species validation, minimizing off-tissue effects
|
-
Tissue-targeted LNPs (liver/brain/lung)
|
|
Custom mRNA-based Cell Reprogramming
|
-
Non-integrating reprogramming factors
|
Generates disease-relevant cells with native proteostasis machinery
|
-
Epigenetic resetting technology
|
|
Custom mRNA Stability Evaluation
|
|
Predicts and extends functional protein expression windows from hours to weeks
|
-
Degradation kinetics modeling
|
Unlock Your Research Potential
Creative Biolabs integrates cutting-edge mRNA technologies to accelerate your protein replacement studies. Our end-to-end platform delivers:
-
Bespoke Experimental Designs: Tailored to your target protein and disease model
-
Native Biological Context: Preserving endogenous cellular machinery
-
Multi-Dimensional Validation: From analytics to functional phenotyping
Request a Custom Proposal
FAQs
Q1: How does your platform improve upon recombinant protein approaches?
A: Our mRNA technology facilitates in situ protein synthesis within native cellular environments, preserving critical post-translational modifications and intracellular trafficking pathways essential for functional mechanism studies. This approach overcomes limitations of recombinant proteins, which lack physiological context due to exogenous production and purification artifacts that disrupt natural protein behavior in research models.
Q2: Can I study protein functions in rare disease models?
A: Yes. We enable species-specific and patient-derived model systems, including iPSC-differentiated cell types coupled with tissue-optimized delivery strategies. This allows investigation of orphan targets such as coagulation factors or rare enzymes in biologically relevant contexts without permanent genetic alterations.
Q3: What level of customization is possible?
A: Customization spans sequence design (codon/UTR optimization, fusion tags), delivery systems (tissue-targeted or microenvironment-responsive carriers), and validation depth (from basic activity assays to spatial transcriptomics). We tailor each project to specific research objectives, whether studying enzyme kinetics in 3D spheroids or tracking protein rescue in genetically engineered models.
Q4: How is data reliability ensured?
A: All studies incorporate multi-dimensional verification: protein localization via multiplexed imaging, functional recovery through disease-specific bioassays, and genomic safety screening. This integrated approach ensures robust mechanistic insights while eliminating technical artifacts common in recombinant protein systems.
Featured mRNA Products
References
-
Fu, Rao, et al. "Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects." Signal Transduction and Targeted Therapy 9.1 (2024): 118. Distributed under Open Access license CC-BY 4.0, without modification. https://doi.org/10.1038/s41392-024-01824-1
-
Li, Dongqiao, et al. "Messenger RNA-based therapeutics and vaccines: what's beyond COVID-19?." ACS Pharmacology & Translational Science 6.7 (2023): 943-969. Distributed under Open Access license CC-BY 4.0, without modification. https://doi.org/10.1021/acsptsci.3c00047
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
